Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

York Medical's DiaCIM will be administered to cancer patients

Sep. 18, 1998

Techniclone submits phase II TNT protocol to FDA

Sep. 18, 1998

Maxim enters collaborative agreement with BioNative

Sep. 15, 1998

Imutec reports positive phase I/II results for Virulizin

Sep. 7, 1998

New biologic for breast cancer receives advisory committee approval

Sep. 3, 1998

Phase I/II trial provides evidence of potential efficacy of ovarian cancer vaccine

Sep. 2, 1998

Medarex receives milestone payment from Merck KGaA

Sep. 2, 1998

Techniclone advancing development of Tumor Necrosis Therapy into phase II

Sep. 2, 1998

Pivotal clinical trial data for rituximab published

Aug. 28, 1998

Imutec receives patent protection for Virulizin in Canada

Aug. 24, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...